Guidelines for diagnosis, treatment, and prevention of clostridium difficile infections

Christina M. Surawicz, Lawrence J. Brandt, David G. Binion, Ashwin N. Ananthakrishnan, Scott R. Curry, Peter H. Gilligan, Lynne V. McFarland, Mark Mellow, Brian S. Zuckerbraun

Research output: Contribution to journalArticle

914 Citations (Scopus)

Abstract

Clostridium difficile infection (CDI) is a leading cause of hospital-associated gastrointestinal illness and places a high burden on our health-care system. Patients with CDI typically have extended lengths-of-stay in hospitals, and CDI is a frequent cause of large hospital outbreaks of disease. This guideline provides recommendations for the diagnosis and management of patients with CDI as well as for the prevention and control of outbreaks while supplementing previously published guidelines. New molecular diagnostic stool tests will likely replace current enzyme immunoassay tests. We suggest treatment of patients be stratified depending on whether they have mild-to-moderate, severe, or complicated disease. Therapy with metronidazole remains the choice for mild-to-moderate disease but may not be adequate for patients with severe or complicated disease. We propose a classification of disease severity to guide therapy that is useful for clinicians. We review current treatment options for patients with recurrent CDI and recommendations for the control and prevention of outbreaks of CDI.

Original languageEnglish (US)
Pages (from-to)478-498
Number of pages21
JournalAmerican Journal of Gastroenterology
Volume108
Issue number4
DOIs
StatePublished - Apr 2013

Fingerprint

Clostridium Infections
Clostridium difficile
Guidelines
Disease Outbreaks
Therapeutics
Molecular Pathology
Metronidazole
Infection Control
Immunoenzyme Techniques
Routine Diagnostic Tests
Length of Stay
Delivery of Health Care

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Surawicz, C. M., Brandt, L. J., Binion, D. G., Ananthakrishnan, A. N., Curry, S. R., Gilligan, P. H., ... Zuckerbraun, B. S. (2013). Guidelines for diagnosis, treatment, and prevention of clostridium difficile infections. American Journal of Gastroenterology, 108(4), 478-498. https://doi.org/10.1038/ajg.2013.4

Guidelines for diagnosis, treatment, and prevention of clostridium difficile infections. / Surawicz, Christina M.; Brandt, Lawrence J.; Binion, David G.; Ananthakrishnan, Ashwin N.; Curry, Scott R.; Gilligan, Peter H.; McFarland, Lynne V.; Mellow, Mark; Zuckerbraun, Brian S.

In: American Journal of Gastroenterology, Vol. 108, No. 4, 04.2013, p. 478-498.

Research output: Contribution to journalArticle

Surawicz, CM, Brandt, LJ, Binion, DG, Ananthakrishnan, AN, Curry, SR, Gilligan, PH, McFarland, LV, Mellow, M & Zuckerbraun, BS 2013, 'Guidelines for diagnosis, treatment, and prevention of clostridium difficile infections', American Journal of Gastroenterology, vol. 108, no. 4, pp. 478-498. https://doi.org/10.1038/ajg.2013.4
Surawicz, Christina M. ; Brandt, Lawrence J. ; Binion, David G. ; Ananthakrishnan, Ashwin N. ; Curry, Scott R. ; Gilligan, Peter H. ; McFarland, Lynne V. ; Mellow, Mark ; Zuckerbraun, Brian S. / Guidelines for diagnosis, treatment, and prevention of clostridium difficile infections. In: American Journal of Gastroenterology. 2013 ; Vol. 108, No. 4. pp. 478-498.
@article{639452a7f3a04a3a991c597e9bd2f067,
title = "Guidelines for diagnosis, treatment, and prevention of clostridium difficile infections",
abstract = "Clostridium difficile infection (CDI) is a leading cause of hospital-associated gastrointestinal illness and places a high burden on our health-care system. Patients with CDI typically have extended lengths-of-stay in hospitals, and CDI is a frequent cause of large hospital outbreaks of disease. This guideline provides recommendations for the diagnosis and management of patients with CDI as well as for the prevention and control of outbreaks while supplementing previously published guidelines. New molecular diagnostic stool tests will likely replace current enzyme immunoassay tests. We suggest treatment of patients be stratified depending on whether they have mild-to-moderate, severe, or complicated disease. Therapy with metronidazole remains the choice for mild-to-moderate disease but may not be adequate for patients with severe or complicated disease. We propose a classification of disease severity to guide therapy that is useful for clinicians. We review current treatment options for patients with recurrent CDI and recommendations for the control and prevention of outbreaks of CDI.",
author = "Surawicz, {Christina M.} and Brandt, {Lawrence J.} and Binion, {David G.} and Ananthakrishnan, {Ashwin N.} and Curry, {Scott R.} and Gilligan, {Peter H.} and McFarland, {Lynne V.} and Mark Mellow and Zuckerbraun, {Brian S.}",
year = "2013",
month = "4",
doi = "10.1038/ajg.2013.4",
language = "English (US)",
volume = "108",
pages = "478--498",
journal = "American Journal of Gastroenterology",
issn = "0002-9270",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - Guidelines for diagnosis, treatment, and prevention of clostridium difficile infections

AU - Surawicz, Christina M.

AU - Brandt, Lawrence J.

AU - Binion, David G.

AU - Ananthakrishnan, Ashwin N.

AU - Curry, Scott R.

AU - Gilligan, Peter H.

AU - McFarland, Lynne V.

AU - Mellow, Mark

AU - Zuckerbraun, Brian S.

PY - 2013/4

Y1 - 2013/4

N2 - Clostridium difficile infection (CDI) is a leading cause of hospital-associated gastrointestinal illness and places a high burden on our health-care system. Patients with CDI typically have extended lengths-of-stay in hospitals, and CDI is a frequent cause of large hospital outbreaks of disease. This guideline provides recommendations for the diagnosis and management of patients with CDI as well as for the prevention and control of outbreaks while supplementing previously published guidelines. New molecular diagnostic stool tests will likely replace current enzyme immunoassay tests. We suggest treatment of patients be stratified depending on whether they have mild-to-moderate, severe, or complicated disease. Therapy with metronidazole remains the choice for mild-to-moderate disease but may not be adequate for patients with severe or complicated disease. We propose a classification of disease severity to guide therapy that is useful for clinicians. We review current treatment options for patients with recurrent CDI and recommendations for the control and prevention of outbreaks of CDI.

AB - Clostridium difficile infection (CDI) is a leading cause of hospital-associated gastrointestinal illness and places a high burden on our health-care system. Patients with CDI typically have extended lengths-of-stay in hospitals, and CDI is a frequent cause of large hospital outbreaks of disease. This guideline provides recommendations for the diagnosis and management of patients with CDI as well as for the prevention and control of outbreaks while supplementing previously published guidelines. New molecular diagnostic stool tests will likely replace current enzyme immunoassay tests. We suggest treatment of patients be stratified depending on whether they have mild-to-moderate, severe, or complicated disease. Therapy with metronidazole remains the choice for mild-to-moderate disease but may not be adequate for patients with severe or complicated disease. We propose a classification of disease severity to guide therapy that is useful for clinicians. We review current treatment options for patients with recurrent CDI and recommendations for the control and prevention of outbreaks of CDI.

UR - http://www.scopus.com/inward/record.url?scp=84875952150&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875952150&partnerID=8YFLogxK

U2 - 10.1038/ajg.2013.4

DO - 10.1038/ajg.2013.4

M3 - Article

C2 - 23439232

AN - SCOPUS:84875952150

VL - 108

SP - 478

EP - 498

JO - American Journal of Gastroenterology

JF - American Journal of Gastroenterology

SN - 0002-9270

IS - 4

ER -